GEN8d
AstraZeneza Commits Up to $11B+ to Chinese Collaborations, Beijing R&D Hub
AstraZeneca will carry out potentially more than $11 billion worth of collaborations in China that include partnerships with three Chinese-based companies to develop drugs and vaccines, as well ...
Merck inks a licensing deal worth nearly $2B with China’s Jiangsu Hengrui
Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui ...
Zacks.com on MSN2d
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug
Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...
MT Newswires on MSN3d
Merck Strikes Nearly $2 Billion Licensing Deal For Chinese Firm's Heart Disease Drug Candidate
Merck (MRK) secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. The companies said Tuesday that ...